Search results for "Genetic Testing"

showing 10 items of 193 documents

World-wide variation in Drosophila melanogaster sex pheromone: behavioural effects, genetic bases and potential evolutionary consequences

1996

0016-6707 (Print) Journal Article Research Support, Non-U.S. Gov't; In Drosophila melanogaster, male wing vibration, a key element of courtship behaviour, is most efficiently induced by a female-specific contact pheromone cis, cis 7,11 heptacosadiene (7,11 HD), which is the main mature female cuticular hydrocarbon in the CS laboratory strain. A study of 63 strains from around the world revealed that flies from Sub-Saharan Africa and the Caribbean are unique in showing low levels 7,11 HD and high levels of the position isomer 5,9 HD. This difference maps to chromosome III, perhaps indicating a simple genetic control of the 7,11 HD:5,9 HD ratio. Females from strains with high levels of 7,11 H…

0106 biological sciencesMaleEvolutionSexual BehaviorVariation (Genetics)Plant Science010603 evolutionary biology01 natural sciencesSex Attractants/*analysis/genetics03 medical and health sciencesSexual Behavior AnimalSpecies SpecificityGeneticsMelanogasterAnimal/*physiologyAnimalsGenetic TestingMatingSex Attractants030304 developmental biologyGenetics0303 health sciencesbiologyCourtship displayGenetic ScreeningStrain (biology)ChromosomeGenetic VariationChromosome MappingGeneral Medicinebiology.organism_classificationBiological Evolution3. Good healthDrosophila melanogasterInsect ScienceSex pheromoneDrosophila melanogaster/chemistry/*physiologyPheromoneAnimal Science and ZoologyFemaleDrosophila melanogaster
researchProduct

Type of chromosome abnormality affects embryo morphology dynamics.

2016

Objective To study the differences in the cleavage time between types of embryo chromosomal abnormalities and elaborate algorithm to exclude aneuploid embryos according to the likelihood to be euploid. Design Retrospective cohort study. Setting University affiliated private center. Patient(s) Preimplantational genetic screening patients (n = 112) including cases of advanced maternal age, repeated implantation failure, and recurrent miscarriage. A total of 485 embryos were analyzed. Intervention(s) None. Main Outcome Measure(s) All biopsied embryos were cultured in an incubator with time-lapse technology, cleavage timing from insemination to day 3 and all kinetic parameters that have been de…

0301 basic medicineAdultBiopsyAneuploidyEmbryonic DevelopmentChromosome DisordersFertilization in VitroBiologyTime-Lapse ImagingAndrology03 medical and health sciences0302 clinical medicinePredictive Value of TestsPregnancyRisk FactorsRecurrent miscarriagemedicineOdds RatioChromosomes HumanHumansAdvanced maternal ageGenetic TestingPreimplantation DiagnosisRetrospective StudiesGeneticsChromosome AberrationsComparative Genomic Hybridization030219 obstetrics & reproductive medicineMicroscopy VideoObstetrics and GynecologyRetrospective cohort studyEmbryoOdds ratiomedicine.diseaseAneuploidyConfidence intervalKinetics030104 developmental biologyBlastocystLogistic ModelsReproductive Medicineembryonic structuresChromosome abnormalityFemaleFertility and sterility
researchProduct

What is the impact of a novel MED12 variant on syndromic conotruncal heart defects? Analysis of case report on two male sibs

2020

Abstract Background Syndromic congenital heart disease accounts for 30% of cases and can be determined by genetic, environmental or multifactorial causes. In many cases the etiology remains uncertain. Many known genes are responsible for specific morphopathogenetic mechanisms during the development of the heart whose alteration can determine specific phenotypes of cardiac malformations. Case presentation We report on two cases of association of conotruncal heart defect with facial dysmorphisms in sibs. In both cases the malformations’ identification occurred by ultrasound in the prenatal period. It was followed by prenatal invasive diagnosis. The genetic analysis revealed no rearrangements …

0301 basic medicineAdultHeart Defects CongenitalMaleHeart diseaseFacial dysmorphismCase ReportGenetic analysisFacial dysmorphismsCongenital heart diseases030218 nuclear medicine & medical imagingConotruncal heart defectsMED1203 medical and health sciences0302 clinical medicinePregnancyNext generation sequencingPrenatal DiagnosismedicineHumansGenetic TestingGeneX chromosomeConotruncal heart defectsCongenital heart diseaseGeneticsMediator Complexbusiness.industrylcsh:RJ1-570lcsh:Pediatricsmedicine.diseasePhenotypeMED12Fetal Diseases030104 developmental biologyConotruncal heart defectEchocardiographyEtiologyFemalebusinessItalian Journal of Pediatrics
researchProduct

Reducing diagnostic turnaround times of exome sequencing for families requiring timely diagnoses

2017

IF 2.137; International audience; BACKGROUND AND OBJECTIVE:Whole-exome sequencing (WES) has now entered medical practice with powerful applications in the diagnosis of rare Mendelian disorders. Although the usefulness and cost-effectiveness of WES have been widely demonstrated, it is essential to reduce the diagnostic turnaround time to make WES a first-line procedure. Since 2011, the automation of laboratory procedures and advances in sequencing chemistry have made it possible to carry out diagnostic whole genome sequencing from the blood sample to molecular diagnosis of suspected genetic disorders within 50 h. Taking advantage of these advances, the main objective of the study was to impr…

0301 basic medicineAdultMaleExome sequencingmedicine.medical_specialtyTime FactorsAdolescentGenetic counselingBioinformaticsTurnaround timeSensitivity and SpecificityUndiagnosed genetic conditions03 medical and health sciencesGeneticsmedicineHumansExomeGenetic TestingMedical diagnosisIntensive care medicineChildExomeGenetics (clinical)Exome sequencingGenetic testingWhole genome sequencing[SDV.GEN]Life Sciences [q-bio]/Geneticsmedicine.diagnostic_testbusiness.industryInfant NewbornInfantGeneral MedicineSequence Analysis DNADiagnostic turnaround time3. Good healthClinical trial030104 developmental biologyEarly DiagnosisChild PreschoolFemalebusiness[ SDV.GEN ] Life Sciences [q-bio]/Genetics
researchProduct

Genetics of Wilson disease and Wilson-like phenotype in a clinical series from eastern Spain.

2019

Wilson's disease (WD) is an autosomal recessive disorder caused by ATP7B mutations. Subjects with only one mutation may show clinical signs and individuals with biallelic changes may remain asymptomatic. We aimed to achieve a conclusive genetic diagnosis for 34 patients clinically diagnosed of WD. Genetic analysis comprised from analysis of exons to WES (whole exome sequencing), including promoter, introns, UTRs (untranslated regions), besides of study of large deletions/duplications by MLPA (multiplex ligation-dependent probe amplification). Biallelic ATP7B mutations were identified in 30 patients, so that four patients were analyzed using WES. Two affected siblings resulted to be compound…

0301 basic medicineAdultMaleNerve Tissue Proteins030105 genetics & heredityBiologymedicine.disease_causeCompound heterozygosityGenetic analysis03 medical and health sciencesExonHepatolenticular DegenerationExome SequencingGeneticsmedicineHumansGenetic Predisposition to DiseaseMultiplex ligation-dependent probe amplificationGenetic TestingGenetics (clinical)Exome sequencingGeneticsMutationExonsmedicine.diseaseWilson's disease030104 developmental biologyPhenotypeCopper-Transporting ATPasesSpainMutationFemaleCongenital disorder of glycosylationClinical geneticsREFERENCES
researchProduct

Molecular diagnosis of PIK3CA-related overgrowth spectrum (PROS) in 162 patients and recommendations for genetic testing.

2017

Postzygotic activating mutations of PIK3CA cause a wide range of mosaic disorders collectively referred to as PIK3CA-related overgrowth spectrum (PROS). We describe the diagnostic yield and characteristics of PIK3CA sequencing in PROS. We performed ultradeep next-generation sequencing (NGS) of PIK3CA in various tissues from 162 patients referred to our clinical laboratory and assessed diagnostic yield by phenotype and tissue tested. We identified disease-causing mutations in 66.7% (108/162) of patients, with mutant allele levels as low as 1%. The diagnostic rate was higher (74%) in syndromic than in isolated cases (35.5%; P = 9.03 × 10−5). We identified 40 different mutations and found stro…

0301 basic medicineAdultMalePathologymedicine.medical_specialtyAdolescentGenotypeClass I Phosphatidylinositol 3-KinasesPrenatal diagnosisBioinformaticsmedicine.disease_causeDNA sequencing03 medical and health sciencesYoung Adult0302 clinical medicinePrenatal DiagnosisGenotypemedicineHumansGenetic Predisposition to DiseaseGenetic TestingAlleleChildGenetics (clinical)AllelesGenetic Association StudiesGrowth DisordersGenetic testingMutationmedicine.diagnostic_testbusiness.industryMosaicismInfant NewbornDisease ManagementHigh-Throughput Nucleotide SequencingInfantSequence Analysis DNAPhenotype030104 developmental biologyPhenotypeAmino Acid SubstitutionChild PreschoolMutationAllelic heterogeneityFemalebusiness030217 neurology & neurosurgeryGenetics in medicine : official journal of the American College of Medical Genetics
researchProduct

Incidental findings in a series of 2500 gene panel tests for a genetic predisposition to cancer: Results and impact on patients.

2020

Abstract With next generation sequencing, physicians are faced with more complex and uncertain data, particularly incidental findings (IF). Guidelines for the return of IF have been published by learned societies. However, little is known about how patients are affected by these results in a context of oncogenetic testing. Over 4 years, 2500 patients with an indication for genetic testing underwent a gene cancer panel. If an IF was detected, patients were contacted by a physician/genetic counsellor and invited to take part in a semi-structured interview to assess their understanding of the result, the change in medical care, the psychological impact, and the transmission of results to the f…

0301 basic medicineAdultMalemedicine.medical_specialtyPatientsContext (language use)030105 genetics & heredity03 medical and health sciencesNeoplasmsGeneticsmedicineGenetic predispositionHumansGenetic Predisposition to DiseaseGenetic TestingCHEK2Genetics (clinical)Genetic testingAgedIncidental Findingsmedicine.diagnostic_testbusiness.industryCancerRegretGeneral MedicineMiddle Agedmedicine.disease030104 developmental biologyAttitudeFamily medicineAnxietyFemalemedicine.symptomReturn of resultsbusinessEuropean journal of medical genetics
researchProduct

Preimplantation genetic testing for aneuploidy in patients with partial X monosomy using their own oocytes: is this a suitable indication?

2019

Objective To describe the outcome of preimplantation genetic testing (PGT-A) using their own oocytes in patients with mosaic Turner Syndrome (MTS). The impact of the assisted reproduction technique (ART) performed (PGT-A or oocyte donation) and the type of absence of the X chromosome (total or partial) were considered. Design Retrospective observational multicenter study. Setting University-affiliated private in vitro fertilization center. Patient(s) Fifty-six patients with MTS with whom 65 ovarian stimulation cycles for PGT-A (fluorescence in situ hybridization/arrays-next generation sequencing) were performed. The study included 90 women with MTS and 20 women with pure Turner Syndrome (PT…

0301 basic medicineAdultmedicine.medical_specialtyMonosomyAneuploidyOocyte RetrievalTurner SyndromeFertilization in Vitro03 medical and health sciences0302 clinical medicinePredictive Value of TestsPregnancyTurner syndromemedicineHumansGenetic TestingX chromosomeIn Situ Hybridization FluorescencePreimplantation DiagnosisRetrospective StudiesGynecologyChromosomes Human X030219 obstetrics & reproductive medicinemedicine.diagnostic_testOocyte Donationbusiness.industryObstetrics and GynecologyHigh-Throughput Nucleotide Sequencingmedicine.diseaseAneuploidyConfidence intervalEmbryo transfer030104 developmental biologyFertilityReproductive MedicineSpainInfertilityOocytesFemaleLive birthbusinessFluorescence in situ hybridizationFertility and sterility
researchProduct

Targeted Re-Sequencing Emulsion PCR Panel for Myopathies: Results in 94 Cases.

2016

BACKGROUND Molecular diagnostics in the genetic myopathies often requires testing of the largest and most complex transcript units in the human genome (DMD, TTN, NEB). Iteratively targeting single genes for sequencing has traditionally entailed high costs and long turnaround times. Exome sequencing has begun to supplant single targeted genes, but there are concerns regarding coverage and needed depth of the very large and complex genes that frequently cause myopathies. OBJECTIVE To evaluate efficiency of next-generation sequencing technologies to provide molecular diagnostics for patients with previously undiagnosed myopathies. METHODS We tested a targeted re-sequencing approach, using a 45…

0301 basic medicineBiologyPolymerase Chain ReactionMuscular Dystrophies03 medical and health sciencesExon0302 clinical medicineMuscular DiseasesHumansGenetic TestingGeneExomeExome sequencingGeneticsMassive parallel sequencingHigh-Throughput Nucleotide SequencingSequence Analysis DNAMolecular diagnostics030104 developmental biologyNeurologyMolecular Diagnostic TechniquesRe sequencingMutationHuman genomeNeurology (clinical)030217 neurology & neurosurgery
researchProduct

Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts

2020

International audience; Treatment with immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) or its ligand (PD-L1) can generate durable responses in various cancer types, but only in a subset of patients. The use of predictive biomarkers for response to PD-1/PD-L1 inhibitors is critical for patient selection. Expression of PD-L1 has demonstrated utility in patient selection. Tumour mutational burden (TMB) is an emerging biomarker for response to PD-1/PD-L1 inhibitors. The evaluation of this biomarker is based on the hypothesis that a high number of mutations in somatic exonic regions will lead to an increase in neoantigen production, which could then be recognised by…

0301 basic medicineCancer ResearchImmune checkpoint inhibitorsmedicine.medical_treatment[SDV]Life Sciences [q-bio]DNA Mutational AnalysisProgrammed Cell Death 1 ReceptorTumour mutational burdenBioinformaticsArticleB7-H1 Antigen03 medical and health sciencesAntineoplastic Agents Immunological0302 clinical medicineImmune systemNeoplasmsBiomarkers TumorHumansMedicineIn patientGenetic TestingPredictive biomarkerbusiness.industryPatient SelectionCancerBiomarkerImmunotherapymedicine.disease3. Good healthBiomarker (cell)[SDV] Life Sciences [q-bio]030104 developmental biologyOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisMutationImmunotherapybusinessCD8
researchProduct